Shenzhen Shenxin Biotechnology Co., Ltd

This study is testing a new mRNA vaccine designed to protect older adults from Respiratory Syncytial Virus (RSV), a common cause of serious lung infections. It will enroll 500 healthy participants aged 60 and older to check the vaccine's safety and how well it triggers an immune …